Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
about
Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).CBDCA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung Adenocarcinoma Resistant to Gefitinib.Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategiesCustomised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC)Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized TherapyFirst line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases.Bevacizumab in advanced lung cancer: state of the art.Venous Thromboembolism in Patients Diagnosed With Lung Cancer.Strategies targeting angiogenesis in advanced non-small cell lung cancer.Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.
P2860
Q33428645-540C2D8D-8844-44DF-9594-2FFFA07B46F7Q36382921-C4CF11AE-81B1-4B40-AE3A-9556AECAF0EAQ36850900-8ED7C779-B1AC-4B4C-AFEB-566DEEDE75F7Q36996220-56CCE544-BC85-468D-91F9-FDF61180CCEAQ36999705-F4E971C0-F6D1-4C9D-AC3D-2B69E282D8DEQ37081896-B92B516A-8CDB-42F0-92A5-78CF444959C9Q37347532-1D239D78-040A-41CC-A547-07EBB99EAA63Q37419857-A35ABF72-107E-4733-A3DE-F28E753C5C40Q37581974-E025AEA1-D6B9-4E86-BD63-0274E5E9B23AQ38641871-253B2D8B-581E-4B5D-9509-4725ABD289CCQ38944457-A476E7FC-20DF-449D-B455-E1F037F8CAE4Q41593429-DB6B1E64-079C-4311-A0AD-81DBC1BA2AB7Q48084391-4C493769-4E7A-4311-AB10-60210BA284F5Q55069554-70251B13-4B32-438C-8BA3-7C1175474F31
P2860
Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase 2 trial of maintenance b ...... ous nonsmall cell lung cancer.
@ast
Phase 2 trial of maintenance b ...... ous nonsmall cell lung cancer.
@en
type
label
Phase 2 trial of maintenance b ...... ous nonsmall cell lung cancer.
@ast
Phase 2 trial of maintenance b ...... ous nonsmall cell lung cancer.
@en
prefLabel
Phase 2 trial of maintenance b ...... ous nonsmall cell lung cancer.
@ast
Phase 2 trial of maintenance b ...... ous nonsmall cell lung cancer.
@en
P2093
P2860
P356
P1433
P1476
Phase 2 trial of maintenance b ...... ous nonsmall cell lung cancer.
@en
P2093
Alexandre Hageboutros
Barry Milcarek
Beth Eaby-Sandy
Corey J Langer
James P Stevenson
Kimberly Krieger
Kumar Rajagopalan
Mona Jacobs-Small
Nikolas Dyanick
Robert A Somer
P2860
P304
P356
10.1002/CNCR.27576
P407
P577
2012-04-27T00:00:00Z